Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

2111 with DOI

4 strong · 9 moderate · 8 weak

Compilations

12026-05-10T22:14:07.958Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

31last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:30:11.422Z

notice · info card · emergency

Searches

172 with no results

queries and counts on the build

Claims checked

5443 supported

43 supported · 11 not

Correspondence

0received

consent field ships in Phase 4

Edges

192

derivations recorded for this entity

Complete over 21 sources, 1 compilation, and 31 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/5-meo-amt/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-09-07srcSerotonin toxicity of serotonergic psychedelics
  4. 2026-09-07src5-Methoxy-alpha-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex.
  5. 2026-09-07srcReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
  6. 2026-09-07srcA systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT).
  7. 2026-09-07srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
  8. 2026-09-07srcCardiac Consequences Associated with Psychedelic Use: A Systematic Review of LSD, MDMA, and 5-HT2B-Mediated Valvular Heart Disease.
  9. 2026-09-07srcEffects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy-N,N-diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice.
  10. 2026-09-07srcAbuse liability profile of three substituted tryptamines
  11. 2026-09-07srcMicrodosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins
  12. 2026-09-07srcUPLC-LTQ-Orbitrap Study on Rat Urinary Metabolites of 5-Methoxy-Alpha-Methyltryptamine.
  13. 2026-09-07srcClinical toxicology of newer recreational drugs.
  14. 2026-09-07srcOxidation of 5-methoxy-N,N-diisopropyltryptamine in rat liver microsomes and recombinant cytochrome P450 enzymes.
  15. 2026-09-07srcIn vitro screening of psychoactive drugs by [(35)S]GTPgammaS binding in rat brain membranes.
  16. 2026-09-07src5-MeO-AMT: Comprehensive Profile
  17. 2026-09-07srcSchedules of Controlled Substances: Placement of 5-MeO-AMT and others in Schedule I — Proposed Rule [Later Withdrawn]
  18. 2026-09-07srcSchedules of Controlled Substances: Withdrawal of Proposed Rule (5-MeO-AMT et al.)
  19. 2026-09-07src5-MeO-AMT History
  20. 2026-09-07src5-MeO-AMT: NCATS Inxight Drugs
  21. 2026-09-07src5-MeO-AMT Fast Facts
  22. 2026-09-07src5-MeO-AMT: Harm reduction information
  23. 2026-09-07src5-MeO-AMT Basics (Erowid Vault)
  24. 2026-09-04issueIssued emergency
  25. 2026-09-04issueIssued info_card
  26. 2026-09-04issueIssued notice
  27. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  28. 2026-06-04publicationPublication — backfill
  29. 2026-05-10revisionRevision 1
  30. 2026-05-10absenceSearched ClinicalTrials.gov for "5-MeO-AMT 5-methoxy-alpha-methyltryptamine" — no results
  31. 2026-05-10absenceSearched PubMed for "5-methoxy-alpha-methyltryptamine toxicity adverse effects case report" — no results
  32. 2026-05-10genGeneration — pipeline-v5 · with 4 morepipeline-v5
  33. 2026-05-10rungeneration run

The same entries, as forms: six forms.